INOVIO PHARMACEUTICALS, INC.
Income Statement
| Line Item | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $30.5M | $42.2M | $35.4M | $40.6M | $10.5M | $13.5M | $4.1M | $9.8M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $95.3M | $98.6M | $88.7M | $57.8M | $34.1M | $21.4M | $18.0M | $20.0M |
| SG&A Expense | $29.3M | $28.3M | $23.9M | $18.1M | $15.9M | $13.6M | $10.8M | $12.0M |
| Operating Income | $-94.1M | $-83.6M | $-76.2M | $-34.3M | $-39.5M | $-19.5M | $-23.5M | $-21.6M |
| Operating Margin | -308.7% | -198.1% | -215.5% | -84.5% | -377.7% | -145.1% | -570.4% | -220.9% |
| Interest Expense | $0 | $25.9K | — | — | — | — | — | — |
| Pretax Income | $-94.8M | $-88.2M | $-73.7M | $-31.2M | $-36.1M | $-66.1M | — | — |
| Income Tax Expense | $2.2M | $0 | $0 | $-2.1M | $0 | $0 | $30.0K | $27.0K |
| Net Income | $-97.0M | $-88.2M | $-73.7M | $-29.2M | $-36.1M | $-66.0M | $-19.7M | $-15.3M |
| Net Margin | -318.1% | -208.9% | -208.5% | -71.9% | -345.4% | -490.3% | -477.6% | -155.7% |
| EPS (Basic) | $-1.05 | $-1.08 | $-1.01 | $-0.43 | $-0.61 | $-1.43 | $-0.58 | $-0.12 |
| EPS (Diluted) | $-1.05 | $-1.09 | $-1.01 | $-0.44 | $-0.64 | $-1.43 | $-0.58 | $-0.12 |
| Shares Outstanding (Basic) | 92.5M | 81.8M | 73.2M | 68.2M | 59.1M | 46.1M | 34.1M | 135.0M |
| Shares Outstanding (Diluted) | 92.5M | 81.9M | 73.2M | 68.4M | 59.4M | 46.1M | 34.1M | 135.0M |
| Dividends Per Share | — | — | — | — | — | — | — | — |